Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pelaia

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Clinical Medicine|August 12, 2023
Left Atrial Strain in Cardiomyopathies and Congenital Heart Disease: A Call for Its Integration into Clinical PracticeGiulia Pelaia, Daniela Concolino, Jolanda Sabatino
Biomedicines|September 23, 2022
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe AsthmaAlessandro Vatrella, Angelantonio Maglio, Corrado Pelaia, et al.
International Journal of Molecular Sciences|April 30, 2021
Tezepelumab: A Potential New Biological Therapy for Severe Refractory AsthmaCorrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Journal of Clinical Medicine|February 11, 2023
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life SettingCarolina Vitale, Angelantonio Maglio, Corrado Pelaia, et al.
Biomedicines|September 28, 2021
Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe AsthmaCorrado Pelaia, Giulia Pelaia, Federico Longhini, et al.
Minerva Medica|February 8, 2021
Biologics in severe asthmaCorrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Journal of Clinical Medicine|May 27, 2023
Pathobiology of Type 2 Inflammation in Asthma and Nasal PolyposisCorrado Pelaia, Giulia Pelaia, Angelantonio Maglio, et al.
Vaccines|June 24, 2022
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13Corrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
International Journal of Molecular Sciences|February 11, 2023
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life StudyAngelantonio Maglio, Carolina Vitale, Corrado Pelaia, et al.
Biomedicines|May 28, 2022
Novel Biological Therapies for Severe Asthma EndotypesCorrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Clinical Medicine|August 12, 2023
Left Atrial Strain in Cardiomyopathies and Congenital Heart Disease: A Call for Its Integration into Clinical PracticeGiulia Pelaia, Daniela Concolino, Jolanda Sabatino
Biomedicines|September 23, 2022
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe AsthmaAlessandro Vatrella, Angelantonio Maglio, Corrado Pelaia, et al.
International Journal of Molecular Sciences|April 30, 2021
Tezepelumab: A Potential New Biological Therapy for Severe Refractory AsthmaCorrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Journal of Clinical Medicine|February 11, 2023
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life SettingCarolina Vitale, Angelantonio Maglio, Corrado Pelaia, et al.
Biomedicines|September 28, 2021
Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe AsthmaCorrado Pelaia, Giulia Pelaia, Federico Longhini, et al.
Minerva Medica|February 8, 2021
Biologics in severe asthmaCorrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Journal of Clinical Medicine|May 27, 2023
Pathobiology of Type 2 Inflammation in Asthma and Nasal PolyposisCorrado Pelaia, Giulia Pelaia, Angelantonio Maglio, et al.
Vaccines|June 24, 2022
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13Corrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
International Journal of Molecular Sciences|February 11, 2023
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life StudyAngelantonio Maglio, Carolina Vitale, Corrado Pelaia, et al.
Biomedicines|May 28, 2022
Novel Biological Therapies for Severe Asthma EndotypesCorrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Pageof 2